Cellular Biomedicine Group to Present at Chinese Biopharmaceutical Association-USA Annual Conference

Rhea-AI Summary

Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) will present at the 25th Annual Conference of the Chinese Biopharmaceutical Association-USA on August 30, 2020, from 10:10 a.m. to 10:35 a.m. EDT, discussing "Building a Competitive Cell Therapy Pipeline for Cancer Patients". Dr. Yihong Yao, Chief Scientific Officer, will lead the session focused on Cell and Gene Therapy. This virtual event will be broadcast from Rockville, MD. CBMG is known for developing innovative therapies for cancer and degenerative diseases, conducting clinical trials in China.

NEW YORK and SHANGHAI, Aug. 26, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, is scheduled for a presentation at the 25^th Annual Conference of the Chinese Biopharmaceutical Association-USA (CBA) to be held online August 29-30, 2020.

Presentation Title:	"Building a Competitive Cell Therapy Pipeline for Cancer Patients"
Session:	Cell and Gene Therapy
Speaker:	Dr. Yihong Yao, Chief Scientific Officer, CBMG
Date:	Sunday, August 30, 2020
Time:	10:10 a.m.to 10:35 a.m. EDT
Location:	Broadcast virtually from Rockville, MD
Website:	https://www.cba-usa.org/content/2020-cba-annual-conference

About Cellular Biomedicine Group, Inc.
Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. The company conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory. The Company's GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. Its Shanghai facility includes a "Joint Laboratory of Cell Therapy" with GE Healthcare and a "Joint Cell Therapy Technology Innovation and Application Center" with Thermo Fisher Scientific. These partnerships focus on improving manufacturing processes for cell therapies. CBMG currently has ongoing CAR-T Phase I clinical trials in China. The China NMPA (formerly CFDA) approved the Company's IND application for a Phase II trial for AlloJoin®, CBMG's "Off-the-Shelf" allogenic haMPC therapy for the treatment of Knee Osteoarthritis (KOA), and has accepted the Company's IND application for a Phase II trial for ReJoin® autologous haMPC therapy for the treatment of KOA. The NMPA has also accepted CBMG's dossier for an IND application for clinical trials of anti-BCMA CAR-T. CBMG is included in the broad-market Russell 3000® Index the small-cap Russell 2000® Index and the Loncar China BioPharma index. To learn more about CBMG, please visit www.cellbiomedgroup.com.

Company Contact:
Derrick C. Li
Head of Strategy and Investor Relations, CBMG
Phone: 917-717-0994
Email: derrick.li@cellbiomedgroup.com 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/cellular-biomedicine-group-to-present-at-chinese-biopharmaceutical-association-usa-annual-conference-301118884.html

SOURCE Cellular Biomedicine Group

FAQ

When is Cellular Biomedicine Group's presentation at the CBA conference?

Cellular Biomedicine Group will present on August 30, 2020.

Who is presenting on behalf of CBMG at the conference?

Dr. Yihong Yao, Chief Scientific Officer, will present for CBMG.

What is the topic of CBMG's presentation at the conference?

The topic is 'Building a Competitive Cell Therapy Pipeline for Cancer Patients'.

What time will CBMG's presentation take place?

The presentation is scheduled from 10:10 a.m. to 10:35 a.m. EDT.

Where is Cellular Biomedicine Group's presentation being held?

The presentation will be held virtually from Rockville, MD.

What is the significance of the CBA conference for CBMG?

The conference provides a platform to showcase CBMG's advancements in cell therapy and immunotherapies.